CalcPep Research

Tesamorelin

FDA Approved

Also known as: Egrifta, TH9507

Track with CalcPep

What is Tesamorelin?

Tesamorelin is an FDA-approved GHRH analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

How It Works

Tesamorelin stimulates the pituitary to release growth hormone, which promotes lipolysis and reduces visceral adipose tissue.

What Research Shows

15
Animal Studies
25
Human Studies

Key Findings:

  • FDA-approved for HIV lipodystrophy
  • Reduces visceral adipose tissue
  • May improve cognitive function in some studies

Dosing Protocol

Typical Dose
2-2 mg
Frequency
Once daily
Route
Subcutaneous injection
Duration
Ongoing

These are general guidelines based on research literature and community protocols. Individual dosing should be determined by a qualified healthcare provider.

Safety & Risks

Reported Side Effects:

Injection site reactionsJoint painSwellingMuscle pain

Contraindications:

  • Active cancer
  • Pregnancy
  • Hypersensitivity to GHRH

Important: This information is for research purposes only. Always consult with a qualified healthcare provider before using any peptide. Never use peptides without proper medical supervision.

Sourcing & Quality

Quality varies significantly between peptide sources. When sourcing Tesamorelin, consider:

  • Third-party testing (HPLC, Mass Spectrometry)
  • Certificate of Analysis (CoA) availability
  • Purity levels (>98% recommended)
  • Beware of LPS (endotoxin) contamination

CalcPep does not sell peptides or recommend specific vendors. Always verify product quality through independent testing.

Quick Facts
Category
Growth Hormone
Status
FDA Approved
Typical Dose
2-2 mg
Route
Subcutaneous injection
Duration
Ongoing
Real-World Data
892
Users Reporting

Aggregated from CalcPep users who have opted in to share anonymous data.

View Full Data

Track Your Protocol

Use CalcPep to calculate doses, log injections, and track your progress.

Get CalcPep